Abstract Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
are myeloproliferative neoplasms (MPNs) associated with high disease burden, reduced …

Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …

Myelofibrosis (MF) is a heterogeneous disorder characterized by splenomegaly,
constitutional symptoms, ineffective hematopoiesis, and an inherent risk of leukemic …

BACKGROUND This analysis of the myeloproliferative neoplasm (MPN) Landmark survey
evaluated gaps between patient perceptions of their disease management and physician …

The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia
and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening …

Essential thrombocythemia (ET) is a Philadelphia chromosome–negative myeloproliferative
neoplasm (MPN) characterized by persistent thrombocytosis, excessive bone marrow …

Splanchnic vein thrombosis (SVT) is one of the vascular complications of myeloproliferative
neoplasms (MPN). We designed a phase 2 clinical trial to evaluate safety and efficacy of …

Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the
treatment of patients with myelofibrosis based on the results of two randomized clinical trials …

Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose
substantial economic and social burdens. To this end, we conducted a nationwide …

Myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential
thrombocythemia (ET), and myelofibrosis (MF) are clonal, progressive, hematological …